Skip to main content

Table 4 Applied dosages and dose modifications of chemotherapy

From: Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients

Treatment and patients Mean dosage Mean number of cycles Patients with dose reduction Patients with delays Mean delay (range) Break-off current therapy line
  % N N (%) N Days %
1st line       
Platinum (n = 248) 96.1 3.9 47 (19.0)* 101 15 (3–52) 57.7
For combination therapy: combined cytotoxic drug (n = 248) 84.1 3.9 146 (58.9)* 101 15 (3–52) 57.7
Monotherapy (n = 60) 82.9 2.2 31 (51.7) 13 14 (7–28) 91.6
2nd line       
Monotherapy (n = 117) 95.4 3.2 20 (17.0) 26 15 (4–49) 77.7
EGFR-TKI (n = 41) ** 4.4 ** ** ** NA
Platinum-basedcombination (n = 18) NA 3.6 14 (77.8) 8 18 (4–31) 55.6
3rd line       
Monotherapy (n = 49) 95.2 2.9 8 (16.3) 9 12 (7–24) 81.6
EGFR-TKI (n = 36) ** 3.4 ** ** ** NA
Platinum-basedcombination (n = 7) NA 3.3 4 (57.1) 3 12 (7–21) 71.4
  1. Patients who entered clinical studies were excluded. EGFR TKI, tyrosine kinase inhibitor targeting the epidermal growth factor receptor. NA, not applicable.
  2. *36 patients (14.5%) received a dose reduction of platinum and combined cytotoxic drug.
  3. **no reliable data available.